Dr. Reddy’s Laboratories Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

12.30$ -0.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Dr. Reddy’s Laboratories Ltd (RDY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Revenue" came in at 353,472 million INR. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of INR.

Tick rows to compare them in a chart (up to 4)

Income Statement RDY
Line item	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	113	10,935	16,604	18,018	20,125	19,472	24,330	65,249	50,006	69,441	70,277	74,693	96,737	116,266	132,170	148,189	154,708	140,809	142,028	153,851	174,600	2,556	214,391	245,879	279,164	325,535	353,472
Cost of Revenue	92	5,715	6,861	7,816	9,366	9,386	12,450	34,301	24,598	32,941	33,937	34,430	43,432	55,687	56,369	62,786	62,427	62,453	65,724	70,421	80,591	1,258	100,551	106,536	115,557	135,107	166,953
Gross Profit	21	5,220	9,743	10,201	10,758	10,086	11,880	30,949	25,408	36,500	36,340	40,263	53,305	60,579	75,801	85,403	92,281	78,356	76,304	83,430	94,009	1,298	113,840	139,343	163,607	190,428	186,519
Research & Development	3.0	507	741	1,371	1,996	2,803	2,158	2,468	3,533	4,037	3,793	5,060	5,911	7,673	12,402	17,449	17,834	19,551	18,265	15,607	15,410	208	17,482	19,381	22,873	27,380	25,314
Selling, General & Administrative	–	71	90	5,020,316	197	6.6	6.8	6.8	14	413	501	532	634	710	646	683	690	715	720	707	50,129	54,559	62,081	46,466	77,201	93,870	59,909
Total Operating Expenses	–	3,734	4,683	6,865	8,674	10,453	10,435	19,698	22,050	25,311	25,729	27,635	34,014	38,778	49,769	59,117	62,662	64,858	64,387	62,542	78,016	866	84,364	82,199	95,878	118,585	137,651
Operating Income	17	1,486	5,060	3,336	2,085	-366	1,446	11,251	3,358	-2,834	2,008	12,628	18,252	21,112	26,032	26,286	29,619	13,498	11,917	20,888	15,993	431	29,476	57,144	67,729	71,843	48,868
Interest Expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1,080	1,668	372	362	1,067	1,018	1,274	1,092	826	634	788	889	14	970	958	1,428	1,711	2,829	3,933
Pre-Tax Income	15	1,060	5,069	3,919	2,546	107	1,892	10,525	3,438	-3,996	2,053	12,443	18,466	21,677	26,606	28,163	27,140	14,653	14,341	22,443	18,032	356	32,298	60,367	71,870	76,784	57,679
Income Tax Expense	1.5	320	154	397	69	-94	259	1,180	-1,229	1,172	985	1,403	4,204	4,900	5,094	5,984	7,127	2,614	4,535	3,648	-1,466	124	8,730	15,300	16,186	19,539	12,996
Net Income	14	739	4,916	3,522	2,480	211	1,633	9,349	4,678	-5,168	1,068	11,040	14,262	16,777	21,512	22,179	20,013	12,039	9,806	18,795	19,498	232	23,568	45,067	55,684	56,544	45,087
EBITDA	–	2,378	6,005	4,351	2,835	1,020	2,707	14,268	7,306	1,486	6,585	16,823	20,331	22,489	33,138	34,386	39,869	24,775	23,627	35,522	41,785	535	45,080	74,431	88,422	96,671	83,294

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings